A novel prognostic signature integrating disulfidptosis- and ferroptosis-related genes in acute myeloid leukemia
Open Access
- 25 August 2025
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-14
Abstract
Acute myeloid leukemia is a highly heterogeneous hematopoietic malignancy, and we constructed a prognostic signature combining disulfidptosis-related genes and ferroptosis-related genes to predict the prognosis, immunotherapy response, and drug sensitivity of acute myeloid leukemia (AML) patients. The TCGA-LAML datasets underwent random partitioning into training and validation sets. Subsequently, a prognostic risk signature was formulated using the least absolute shrinkage and selection operator algorithm. Kaplan–Meier survival analysis and receiver operating characteristic curve analysis were employed to assess the clinical significance of the signature. The results of the immune infiltration difference analyses are displayed, and the drug sensitivity analyses were used to identify potentially effective drugs for AML patients. qPCR was employed to validate the expression levels of the signature genes and compared the signature with existing signatures and mutated genes. Univariate and multivariate Cox regression analyses have underscored the signature as an autonomous prognostic risk determinant. Scrutiny into immune infiltration has unveiled significant associations: the risk score exhibits a favorable correlation with monocyte and M2 macrophage counts but an adverse correlation with resting mast cell counts. The expression patterns of immune checkpoint genes diverge between the distinct risk cohorts. Patients categorized as high-risk demonstrate enhanced benefits from cyclopamine, 443654, and 770041, whereas those classified as low-risk exhibit more pronounced advantages from cytarabine and AZD6244. The risk signature demonstrates superior prognostic accuracy compared to established signatures and mutated genes. In summary, our study may provide potential prognostic biomarkers and individualized precision therapy for AML patients.Keywords
Funding Information
- the Youth Program of Natural Science Foundation of Shandong Province (ZR2020QH172, ZR2020QH172)
- the Distinguished Taishan Scholars in Climbing Plan (tspd20210321)
- The National Natural Science Foundation of China (82070160, 82370165)
- the Fundamental Research Funds for the Central Universities (2022JC012)
- the Key Program of Natural Science Foundation of Shandong Province (ZR2020KH016)
- the Independently Cultivate Innovative Teams of Jinan, Shandong Province (2021GXRC050)
- Young Elite Sponsorship Program of Shandong Provincial Medical Association (2023_LC_0336)
- ECCM Program of Clinical Research Center of Shandong University (2021SDUCRCB008)
- the horizontal subject of Shandong University (6010123101)
This publication has 42 references indexed in Scilit:
- MYB as a Critical Transcription Factor and Potential Therapeutic Target in AML2024
- Lycorine eliminates B-cell acute lymphoblastic leukemia cells by targeting PSAT1 through the serine/glycine metabolic pathwayEuropean Journal of Pharmacology, 2023
- Based on disulfidptosis, revealing the prognostic and immunological characteristics of renal cell carcinoma with tumor thrombus of vena cava and identifying potential therapeutic target AJAP1Journal of Cancer Research and Clinical Oncology, 2023
- Ferroptosis at the intersection of lipid metabolism and cellular signalingMolecular Cell, 2022
- Ferroptosis in the tumor microenvironment: perspectives for immunotherapyTrends in Molecular Medicine, 2021
- A novel 4‐mRNA signature predicts the overall survival in acute myeloid leukemiaAmerican Journal of Hematology, 2021
- Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapyProtein & Cell, 2020
- Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and markedly increases survival rates of miceInternational Journal of Cancer, 2020
- AML in 2017: Advances in clinical practiceBest Practice & Research Clinical Haematology, 2017
- Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and CostsApplied Health Economics and Health Policy, 2013